Eyenovia Announces Participation at the 2023 International Consumer Electronics ShowGlobeNewsWire • 12/20/22
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil DilationGlobeNewsWire • 12/13/22
Hoping Eyenovia Has The Aye Votes From The FDA In The Near Future (Rating Downgrade)Seeking Alpha • 12/13/22
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice PresidentGlobeNewsWire • 12/08/22
Eyenovia, Inc. (EYEN) CEO Michael Rowe on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/11/22
Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/10/22
Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for PresbyopiaGlobeNewsWire • 10/20/22
Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.GlobeNewsWire • 09/30/22
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board MemberGlobeNewsWire • 07/27/22
Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and OperationsGlobeNewsWire • 07/18/22
Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of DirectorsGlobeNewsWire • 07/07/22
Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in ChinaGlobeNewsWire • 07/06/22